8th TIL Therapies Summit 2026

About this event

With the first TIL Therapy now approved in both the US and Canada, and the field regrouping following a setback in Europe, this is a pivotal time for drug developers looking to address treatment-resistant solid tumors.

Returning for its 8th year, the TIL Therapies Summit remains the go-to forum for this close-knit community, created with the mission to transform end-to-end TIL development and deliver best-in-class therapies to treat solid tumor indications with significant unmet needs.

With more patients being treated than ever, this summit unites a global collective of biopharma, academic thought leaders and clinicians including Curacell, Junecell, Obsidian Therapeutics, AgonOx, as they share their cutting-edge research into engineered TIL, easier manufacturing, QC, Potency, clinical updates, regulatory updates, investment opportunities and more.

From Hanson Wade